Page last updated: 2024-08-16

temozolomide and stx-0119

temozolomide has been researched along with stx-0119 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Sugino, T; Yamaguchi, K1
Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Urakami, K; Yamaguchi, K1
Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Ito, M; Kiyohara, Y; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Yamaguchi, K1

Other Studies

3 other study(ies) available for temozolomide and stx-0119

ArticleYear
Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
    International journal of oncology, 2014, Volume: 45, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasms, Experimental; Oxadiazoles; Quinolines; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays

2014
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.
    Cancer genomics & proteomics, 2017, 01-02, Volume: 14, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chitinase-3-Like Protein 1; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Exome; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Male; Oxadiazoles; Protein Kinase Inhibitors; Quinolines; Signal Transduction; STAT3 Transcription Factor; Temozolomide; TOR Serine-Threonine Kinases

2017
The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.
    Immunology letters, 2017, Volume: 190

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; HLA-A2 Antigen; Humans; Leukocytes, Mononuclear; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Knockout; Mice, Nude; Oxadiazoles; Quinolines; STAT3 Transcription Factor; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2017